基本信息 产品详情 公司简介 推荐产品
网站主页 1254472-97-3 化合物 Fezagepras钠盐
  • 化合物 Fezagepras钠盐|T12375|TargetMol

化合物 Fezagepras钠盐|T12375|TargetMol

Fezagepras sodium
1254472-97-3
373 1mg 起订
870 5mg 起订
1410 10mg 起订
上海 更新日期:2024-09-30

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 Fezagepras钠盐
英文名称:
Fezagepras sodium
CAS号:
1254472-97-3
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.59%
产品类别:
抑制剂
货号:
T12375

Product Introduction

Bioactivity

名称Fezagepras sodium
描述Fezagepras sodium (Setogepram sodium salt) is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions.
体外活性PBI-4050 inhibited kidney macrophage infiltration, oxidative stress, and TGF-β-mediated fibrotic signaling pathways, and it also protected against the development of tubulointerstitial fibrosis. To confirm a direct antiinflammatory/antifibrotic effect in the kidney, further studies with a nondiabetic model of EGFR-mediated proximal tubule activation confirmed that PBI-4050 dramatically decreased the development of the associated tubulointerstitial injury and macrophage infiltration[1].
体内活性eNOS-/- db/db mice were treated with PBI-4050 from 8-20 weeks of age (early treatment) or from 16-24 weeks of age (late treatment). PBI-4050 treatment ameliorated the fasting hyperglycemia and abnormal glucose tolerance tests seen in vehicle-treated mice. In addition, PBI-4050 preserved (early treatment) or restored (late treatment) blood insulin levels and increased autophagy in islets. PBI-4050 treatment led to significant improvements in lifespan in the diabetic mice. Both early and late PBI-4050 treatment protected against progression of DN, as indicated by reduced histological glomerular injury and albuminuria, slow decline of glomerular filtration rate, and loss of podocytes[1].
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度H2O : 90.0 mg/mL (394.3 mM)
DMSO : 60 mg/mL (262.86 mM)
关键字Setogepram sodium | PBI-4050 sodium | Fezagepras sodium
相关产品Benzyl nicotinate | CRTh2 antagonist 2 | Ramatroban | CAY10595 | Questiomycin A | TUG-1375 | NF-56-EJ40 | Kynurenic acid | Monomethyl fumarate | 3-Hydroxyoctanoic Acid | Timapiprant | Vincamine
相关库经典已知活性库 | 已知活性化合物库 | 抗衰老化合物库 | 临床期小分子药物库 | 药物功能重定位化合物库
Setogepram sodium salt|||PBI-4050 sodium salt|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 Fezagepras钠盐相关厂家报价

内容声明
拨打电话 立即询价